

Index

a

academic vs. industrial research 299–310
 Binding Database 305
 Cambridge Structural Database (CSD) 305
 clinical trials 308
 Competitive Intelligence (CI) 301
 Crystallography Open Database (COD) 305
 R&D process 301
 Acetaminophen 70, 71
 ADME-Tox 274, 307, 310
 AlphaFold Database 177, 179–180, 192, 279–280
 AlphaFold program 272, 279
 American Chemical Society (ACS) 299
 angiotensin-converting enzyme (ACE) inhibitors 80, 82, 84
 Apixaban 117
 Approved Drugs component 244
 artificial intelligence/machine learning (AI/ML) tools 68
 Asinex 305
 Assay ID (AID) 44
 AutoDock Vina 275
 automatic rebuilding of protein backbone and side chains 203–204

b

BCR–ABL kinase inhibitor 122, 123
 Beilstein 299
 BindingDB Database 283, 305

BioAssay data collections 43
 BioChemGraph project 166
 bioisostere 101
 classical vs. non-classical 102–105
 bioisosteric replacement, in drug discovery 105–106
 bioisosterism 101, 102, 105, 106
 BioMagResBank (BMRB) 141
 BLAST (blastp) algorithm 241
 Boltzmann-Enhanced Discrimination of ROC (BEDROC) 287

c

Cambridge Structural Database (CSD) 42, 152, 305, 311
 carbohydrates 149–150, 155, 204, 214
 Center for Biologics Evaluation and Research (CBER) 310
 Center for Drug Evaluation and Research (CDER) 310
 Charles Rive 305
 ChemAxon 73, 86, 240
 ChEMBL 2, 4, 56, 57, 107, 109, 111, 118, 232, 234, 283, 284, 288, 306, 307
 ChemBridge 305
 chemical abstracts service (CAS) 45, 299
 Chemical Taxonomy 73, 91
 China National Intellectual Property Administration (CNIPA) 302
 ciprofloxacin 118, 120
 classical vs. non-classical bioisostere 102–105

- Classification Browser 51, 52
 3C-like protease (3CLpro) 94
 COLleCtion of Open Natural ProdUcTs (COCONUT) 281, 306
 color-Tanimoto (CT) score 46, 48
 Combo-Tanimoto (ComboT) score 48
 competitive intelligence (CI) 301
 computer-aided drug design (CADD) 1, 2, 311
 computer-aided structure-based drug design 190–191
 COVID-19 94, 111, 164, 191
 COVID Moonshot campaign 164
 COX2 inhibitors 311
 cytochrome peroxidase P450 (CYP) 306
 cytochrome P450 monooxygenase enzymes 212
- d**
- Define Secondary Structure of Proteins (DSSP) analysis 220
 details pages 236
 Deutsches Patent-und Markenamt (DPMA) 302
 Die Pathway Datenbank HumanCyc 307
 Disease Novelty component 246, 248
 DrugBank 2, 68, 305
 categories section 73
 drug cards 70
 identification section 70–71
 knowledgebase 69
 overview of 68–69
 pharmacology 71–73
 properties section 73
 research using 94
 Targets, Enzymes, Carriers, and Transporters section 73–77
 DrugBank Online’s Advanced Search Functionality 80–83
 drug metabolism and pharmacokinetic profile (DMPK) 306
 drug-related non-classical bioisosteres 103
 Drug Target Ontology (DTO) 242
- e**
- EGFR 104
 Electron Microscopy Data Bank (EMDB) 141
 Enamine 305
 enrichment factor (EF) 286
 enzyme inhibitors 84, 85
 Estrogen-related receptor gamma ligand-binding domain 179
 EU Clinical Trials Register 308
 European Nucleotide Archive (ENA) 305
 European Patent Office (EPO) 302
 European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) 309
 Evotec 305
 Expression Data component 243
- f**
- Filter Value Enrichment 248–251, 263
 findability, accessibility, interoperability, and reuse (FAIR) principles 3, 141, 220, 223
 Find Predicted Targets 252
 fingerprint-based 2-D similarity search method 45–46, 48
- g**
- Gaussian-shape overlay-based 3-D similarity methods 45
 Gefitinib 104
 GeneCards 233
 Gene Ontology (GO) 52, 246
 Gene, Protein, Pathway, and Taxonomy collections 43
 Generated DataBases (GDBs) 282
 genome-wide association studies (GWAS) 67, 246
 glycoprotein structure model rebuilding 214
 Gmelin 299
 Google Patents 303
 GWAS Traits component 246

h

high-throughput screening (HTS) 2, 41, 67, 105, 111, 271, 305
 histidine flip and improved ligand parameterization 208–210
 hit finding 105, 106, 108, 117, 133, 305
 human B-raf protein kinase 181
 Human Metabolome Database (HMDB) 306

i

Identifier Exchange Service 52
 isosteres 101
 isosterism 101, 102

j

Japanese Patent Office (JPO) 302

k

KEGG Pathway Database 307

l

lead compounds 105, 106, 118, 124, 129
 lead optimization 105, 106, 108, 120, 133
 Ligand-Based VS (LBVS) 272
 Lipinski's rule of five (Ro5), for drug-likeness 55
 Literature Knowledge Panels 49–50, 60

m

machine learning (ML) 1, 58, 93, 165, 166, 288
 main protease protein (Mpro) 164
 MarvinJS Widget 240, 252
 Maybridge 305
 metabolism 73, 74, 76, 79, 113, 212
 MetaCyc Metabolic Pathway Database 307
 metal binding sites 214–216
 $2mF_o - DF_c$ density map 154
 mitogen activated protein kinase (MAPK) signaling pathway 208
 mmCIF format 3, 4, 218, 278
 ModelArchive 176, 177, 180–181, 192, 193

molecular mechanics-generalized Born surface area (MM-GBSA) strategy 94

molecule-based discovery 68

MONDO disease 261

morpholine 104, 105, 129

n

NCATS Predictor 241, 252, 253

non-classical vs. classical bioisostere 102–105

NorA efflux pump, inhibitor design of 118

normalized ratios of principal moments of inertia (NPR) 115

Nucleic Acid Database (NDB) 304

Nucleic Acid Knowledge Base (NAKB) 304

o

OneDep 145–146, 150, 151, 154

OpenEye 147

OpenTargets 233

p

papain-like protease (PLpro) 94

Patent collection 43

Pathways 73, 79, 246, 251

PDBeChem service 158

PDBe-KnowledgeBase (PDBe-KB) 142

PDBe tools for ligand analysis 155–158

PDB identifier (PDB ID) 278

PDB-REDO databank 278

automated model completion approaches 204–205

automatic rebuilding of protein backbone and side chains 203–204

building new compounds into density 212–213

creating datasets 222

data available in PDB-REDO entries 220

downloading and inspecting individual PDB-REDO entries 218–220

- PDB-REDO databank (*contd.*)
 - FAIR validation data 222
 - first uniformity 203
 - glycoprotein structure model rebuilding 214
 - histidine flip and improved ligand parameterization 208–210
 - loop building
 - completes a binding site region 210, 211
 - results in improved binding sites 211–212
 - metal binding sites 214–216
 - nucleic acid improvements 213
 - overview of pipeline 205–206
 - re-refinement improves ligand conformation 206–207
 - side chain rebuilding improves ligand binding sites 207–208
 - structure models 223
 - systematic integration of structural knowledge 205
 - uniform data 222
- peptide-based chromophores 146
- Peptide Reference Dictionary (PRD) 147–148
- pharmacodynamics 72, 122
- pharmacogenomic effects/ADRs 73
- pharmacogenomics/pharmacogenetics (PGx) 96
- Pharmacological Action field 76, 77
- pharmacology 71–73, 96
- pharmacophores 3, 113, 275–276
- PharmaGist 275
- Pharos 232–264, 306
 - chemical compound 251–260
 - dark target 246, 247
 - downloading Data 251
 - List Analysis 247–248
 - primary documentation 242–247
 - variations 251
 - investigating diseases 260–262
- phenotypic-based discovery 68
- phosphodiesterase 5 (PDE5) inhibitor 310
- pLDDT 179–181, 279
- Ponatinib 122–124
- programmatic access routes 52
- Protein Data Bank (PDB) 2–4, 42, 141–166, 175–178, 181, 182, 189, 192, 278, 304, 307, 311
 - additional ligand annotations 148–150
 - drug discovery 164–165
 - ligand-related annotations 158–164
 - models 201
 - PDBe tools for ligand analysis 155–158
 - small molecule data 142–146
 - small molecule dictionaries 146–148
 - wwPDB 150–155
- Protein Data Bank in Europe (PDBe) 57, 141, 142, 154–156, 158
- Protein Data Bank Japan (PDBj) 141, 304
- protein–ligand docking 271, 274–276, 280
- protein–protein interactions 181, 206, 234, 244, 245, 248, 263
- protein-structure databases
 - AlphaFold DB 279
 - PDB-REDO databank 278
 - Protein Data Bank (PDB) 278
 - SWISS-MODEL Repository 279
- Protein Summary component 238, 242
- PubChem 2, 41, 283, 284
 - biological activity data 56–57
 - Classification Browser 51–52
 - 2D and 3D neighbors 50, 51
 - data collections 43
 - data content and organization 42–44
 - data for drug discovery 58–59
 - data organization 43
 - drug-likeness and lead-likeness of compounds in 54–55
 - Identifier Exchange Service 52
 - Literature Knowledge Panels 49–50
 - programmatic access routes 52

- range of users 41
 - spectral information 42
 - substance and compound records 44
 - Summary page 48, 49
 - tools and services 45–54
 - PubChem Data Sources page 43
 - PubChem FTP Site 53, 54
 - PubChem Help site 45
 - PubChem home page 42, 45
 - PubChemRDF 53, 54
 - PubChem Search 45–48
 - PUG-REST 53
 - PUG-View 53
- q**
- quantitative structure–activity relationship (QSAR) models 2, 241
- r**
- Reactome Pathway 246, 263
 - Real Space Correlation Coefficient (RSCC) 153, 154, 214
 - Reaxys 299, 300
 - ReCore 310
 - Resource Description Framework (RDF) 53, 54
 - RNA-dependent RNA polymerase (RdRp) 94
 - ROC curves 287
- s**
- SARS-CoV-2 M-pro inhibitors 288
 - scaffold hopping 106, 117, 310–311
 - SciFinder 299, 300
 - shape-Tanimoto (ST) score 46, 48
 - Similarity Ensemble Approach (SEA) 3
 - small molecule data 142–146
 - small molecule dictionaries 146–148
 - Small Molecule Pathway Database (SMPDB) 79, 307
 - SMILES format 3, 4, 147, 274
 - SoftFocus® Libraries 306
 - spike (S) protein 94
 - structure-based approaches 1, 3
 - Structure-Based VS (SBVS) 272
 - Substituents field 73
 - Summary page for PubChem 48, 49, 53, 57, 59, 60
 - SwissBioisostere
 - bioactivity data 107
 - biological context 112–113
 - blood–brain barrier diffusion 122, 124
 - chemical context 113
 - construction workflow 107
 - database 108
 - escape from flatland strategy 128–132
 - flexibility reduction 124–128
 - fragments
 - chemical nature and composition of 113, 114
 - global content 111
 - molecular shape distribution 116
 - most frequent user requests 117
 - nonsupervised matched molecular pair analysis 108
 - NorA efflux pump, inhibitor design of 118
 - reduction of aromaticity 128–132
 - rigidification of linkers 126
 - rigidification of scaffolds 127
 - rigidification of side chains 125
 - scaffold replacement request, analysis and interoperability 117–119
 - shape diversity 113, 115
 - web interface 109–111
 - Website usage 115
 - novel antibiotic and insecticide design guided by 120
 - passive absorption, optimization of 122, 124
 - replacing unwanted chemical groups 118–122
 - Swiss Federal Institute of Intellectual Property (IGE-IPI) 302
 - SWISS-MODEL 3, 177–179
 - SWISS-MODEL Repository (SMR) 279
 - associated tools 182–183

- SWISS-MODEL Repository (SMR)
(*contd.*)
- binding site conformational states
189–190
 - Computer-Aided Structure-based Drug
Design 190–191
 - ModelArchive 180–181
 - quality estimates and benchmarking
188–189
 - structural features, ligands and
oligomers 181–182
 - Web and API access 183–187
 - SwissTargetPrediction 3, 118
- t**
- Tanimoto coefficient 240, 241, 254
 - Tanimoto equation 46
 - Target Assessment (TA) 300
 - target-based discovery 67
 - Target Central Resource Database (TCRD)
232
 - analysis methods within Pharos
 - amino acid sequence 241
 - Enrichment scores 241
 - Find Similar Targets 241
 - search for ligands 240
 - targets predicted 241
 - data organization
 - data and UI Updates 235
 - Disease Alignment 234
 - Ligand Alignment 234
 - Target Alignment 234
 - primary resources 233
 - UI Organization 235–236
 - target-centric paradigm 67
 - Target Development Level (TDL) 231,
232
 - Target Illumination GWAS Analytics
(TIGA) 246
 - Targets 79
 - Targets, Enzymes, Carriers, and
Transporters 73, 75–77
 - Tchem proteins 232
 - Tclin proteins 232
 - Tdark proteins 232
 - tetrahydro-1,4-benzoxazepin-5-one
104
 - three-dimensional protein complexes
280, 281
 - Tipranavir 122
 - Toxicology and Environmental Health
Information Program (TEHIP)
307
 - TOXicology Data NETwork (TOXNET)
307
 - tutorials 109, 110, 240
 - tyclopirazoflor 118, 120
 - type IIA DNA topoisomerases 206, 207
- u**
- UI organization 235–240
 - UniProt 4, 75, 77, 162, 178, 233, 234,
242, 246, 261, 279, 307
 - UniProt human protein database 241
 - UniProt ID 4, 75, 79, 83, 234, 284
 - UniProt Knowledgebase (UniProtKB)
176–178, 181–183, 187, 191, 279,
280, 283, 285
 - United States Patent and Trademark
Office (USPTO) 302
 - user support, on SwissBioisostere website
110
- v**
- Validation HElper for LIgands and
Binding Sites (VHELIBS) program
278, 280, 281
 - virtual screening (VS) 311–312
 - bioactive molecules
 - BindingDB database 283
 - ChEMBL 284
 - PubChem 283–284
 - biological activity 286
 - definition 271
 - inactive/decoy molecules database
 - building custom-based decoy sets
286
 - collecting experimentally inactive
compounds from PubChem 285

- collecting presumed inactive
 - compounds from decoy databases 285–286
 - new drugs
 - COCONUT 281
 - Generated DataBases (GDBs) 282
 - ZINC20 282
 - protein-structure databases 277–278
 - tools for 272–274
 - pharmacophore search 275–276
 - protein-ligand docking 274–275
 - shape/electrostatic similarity 276–277
- W**
- Worldwide Protein Data Bank (wwPDB) 3, 141, 150–155
 - wwPDB Chemical Component Dictionary (CCD) 146–147
- X**
- X-ray structure models 201–202, 206, 224
- Z**
- ZINC20 2, 115, 282, 286

